MBOAT7
protein-codingmembrane bound O-acyltransferase domain containing 7, the group of Membrane bound O-acyltransferase family
Gene summary
This gene encodes a member of the membrane-bound O-acyltransferases family of integral membrane proteins that have acyltransferase activity. The encoded protein is a lysophosphatidylinositol acyltransferase that has specificity for arachidonoyl-CoA as an acyl donor. This protein is involved in the reacylation of phospholipids as part of the phospholipid remodeling pathway known as the Land cycle. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Mar 2009]
- LENG4
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~16.5 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0014962
Submitter: PanelApp Australia
Inheritance Pattern: AR
Disease ID:MONDO:0014962
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0014962
Submitter: G2P
Inheritance Pattern: AR
Disease ID:MONDO:0014962
Submitter: Laboratory for Molecular Medicine
This gene-disease relationship has undergone rapid assessment. Classifications are based on preliminary review of gene-disease validity during analysis of genomic sequencing results.
Inheritance Pattern: AR
Disease ID:MONDO:0014962
Submitter: Ambry Genetics
Inheritance Pattern: AR
Disease ID:MONDO:0100038
Submitter: ClinGen
*MBOAT7* encodes an enzyme that regulates arachidonic acid incorporation in lysophosphatidylinositol. *MBOAT7* was first reported in relation to autosomal recessive complex neurodevelopmental disorder in 2016 (Johansen et al., PMID: 27616480). Probands with variants in *MBOAT7* frequently have the phenotypic features of moderate to severe developmental delay, absent speech, infant-onset epilepsy, truncal hypotonia and autistic features. Eight variants (nonsense, frameshift and splice-site) that have been reported in ten probands in four publications (PMIDs: 27616480, 32645526, 31282596, 3335874) are included in this curation. All variants described were homozygous, and one variant, c.758_778del, was reported in three unrelated families. More evidence is available in the literature (PMID: 30701556), but the maximum score for genetic evidence (12 pts.) has been reached. The mechanism of pathogenicity is reported as loss of function (PMID: 27616480). This gene-disease relationship is also supported by a knock-out Mboat7 mouse model (PMID: 23097495). This model showed complete ablation of Mboat7 enzyme activity, an absence of the protein in brain tissue, and displayed atrophy of the cerebral cortex, disordered cortical lamination, and delayed neuron migration. Additionally, expression of two disease-related variants in HepG2 cells (p.(Tyr354*) and p.(Leu379Trpfs*9)) showed absent Mboat7 protein on western blot (PMID: 32645526). In summary, there is definitive evidence supporting the relationship between *MBOAT7* and autosomal recessive complex neurodevelopmental disorder. This has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time. This classification was approved by the ClinGen Intellectual Disability and Autism GCEP on the meeting date November 21, 2023 (SOP Version 10).
Inheritance Pattern: AR
Disease ID:MONDO:0019502
Submitter: Orphanet
Clinical Genomic Database (CGD)
Manifestation: Neurologic
Intervention: General
Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to MBOAT7 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_024298.5. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 2 | 42 | 44 | |||
| missense | 1 | 136 | 5 | 142 | ||
| nonsense | 1 | 6 | 2 | 9 | ||
| start loss | 2 | 2 | ||||
| frameshift | 7 | 12 | 5 | 24 | ||
| splice donor/acceptor (+/-2bp) | 2 | 2 | 6 | 10 | ||
| Total | 10 | 21 | 153 | 47 | 0 | 231 |
Highest pathogenic variant AF is 0.000052546413
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_077274.3 | 7 | MANE Select | |
| Ensembl | ENSP00000245615.1 | 7 | MANE Select | |
| RefSeq | NP_001139528.1 | 5 | Standard | |
| RefSeq | NP_001139554.1 | 6 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Glycerophospholipid metabolism - Homo sapiens (human)
- Acyl chain remodelling of PI
- Metabolism of lipids
- Metabolism
- CDP-diacylglycerol biosynthesis
Biological Process
- phospholipid biosynthetic process
- ventricular system development
- layer formation in cerebral cortex
- phosphatidylinositol acyl-chain remodeling
Molecular Function
- 1-acylglycerol-3-phosphate O-acyltransferase activity
- protein binding
- 2-acylglycerol-3-phosphate O-acyltransferase activity
- lysophospholipid acyltransferase activity
Cellular Component
- endoplasmic reticulum membrane
- membrane
- integral component of membrane
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000245615
- Coding exons
- 7
- Length
- 16627
- Individuals with no LoFs
- 125731
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 15
- Defined
- 125746
- p
- 0.0000596
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 0.441 | 274 | 295 | 0.928 | 0.0000203 | 2959 |
| Missense (PolyPhen) | 74 | 92.4 | 0.80087 | 959 | ||
| Synonymous | -1.51 | 156 | 134 | 1.17 | 0.00000949 | 1020 |
| Loss of Function | 2.85 | 5 | 18.1 | 0.276 | 8.58e-7 | 199 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00019 | 0.00018 | rare |
| Latino/Admixed American | 0.00018 | 0.00017 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0 | 0.0 | absent |
| Finnish | 0.000051 | 0.000046 | rare |
| European (Non-Finnish) | 0.000048 | 0.000044 | rare |
| South Asian | 0 | 0.0 | absent |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Acyltransferase which contributes to the regulation of free arachidonic acid (AA) in the cell through the remodeling of phospholipids. Mediates the conversion of lysophosphatidylinositol (1-acylglycerophosphatidylinositol or LPI) into phosphatidylinositol (1,2-diacyl-sn-glycero-3-phosphoinositol or PI) (LPIAT activity). Prefers arachidonoyl-CoA as the acyl donor. Lysophospholipid acyltransferases (LPLATs) catalyze the reacylation step of the phospholipid remodeling pathway also known as the Lands cycle. Required for cortical lamination during brain development (By similarity). {ECO:0000250|UniProtKB:Q8CHK3, ECO:0000269|PubMed:18094042, ECO:0000269|PubMed:18772128}.;
Intolerance Scores
- LoFtool
- 0.690
- RVIS EVS
- -0.53
- RVIS percentile EVS
- 20.7
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- S
- Essential (gene trap)
- N
- Indispensability pred.
- N
- Indispensability score
- 0.283
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |